Piramal Pharma Limited

Piramal Pharma Limited

Piramal Pharma Limited has released its Sustainability Report for the financial year 2025-26, highlighting its progress in advancing innovation, leveraging sustainability, and addressing key sustainability pillars.

Piramal Pharma Limited

Piramal Pharma Limited has acquired an additional 40.67% stake in Yapan Bio Private Limited, increasing its shareholding from 33.33% to 74.00%. The acquisition was completed for an aggregate cash consideration of approximately ₹76 crores. Yapan has ceased to be an associate company and has become a subsidiary of Piramal Pharma Limited.

Piramal Pharma Limited

Piramal Pharma Limited has informed the Exchange regarding the exercise of a call option to acquire an additional 41% equity stake in Yapan Bio Private Limited, an associate company, from existing shareholders. The acquisition will increase the company's shareholding in Yapan from 33.33% to approximately 74%, making Yapan a subsidiary of Piramal Pharma Limited.

Piramal Pharma Limited

Piramal Pharma Limited has informed the stock exchanges about the schedule of Analyst/Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meetings are scheduled to take place on various dates in September 2026 at different locations in India and Singapore.

Piramal Pharma Limited

Piramal Pharma Limited has resumed operations at its facilities in Ahmedabad, Gujarat, after a temporary suspension due to heavy rainfall and flooding. The company has completed a preliminary assessment and initiated the insurance claim process, with no material impact expected on its operations or financial performance.

Piramal Pharma Limited

Piramal Pharma Limited has informed the Exchange about the transcript of the Conference Call held on 30th July, 2026, on the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended 30th June, 2026, available on the Company’s website.

Piramal Pharma Limited

Piramal Pharma Limited held its 6th Annual General Meeting on July 30, 2026, through video conferencing. The meeting was chaired by Ms. Nandini Piramal, and all resolutions proposed in the notice were passed with the requisite majority. The meeting was webcast live on the e-voting website of National Securities Depository Limited.

Piramal Pharma Limited

Piramal Pharma Limited has made available the audio recording of its conference call on unaudited financial results for the quarter ended 30th June, 2026, on its website.

Piramal Pharma Limited

Piramal Pharma Limited has announced its standalone and consolidated results for the First Quarter (Q1) ended 30th June 2026, with a 17% revenue growth, 72% EBITDA growth, and 12.5% EBITDA margin.

Piramal Pharma Limited

Piramal Pharma Limited has announced its Q1 FY27 results, with a 17% revenue growth, 72% EBITDA growth, and 12.5% EBITDA margin expansion. The company's CDMO business delivered broad-based growth, while its Complex Hospital Generics and Consumer Healthcare businesses maintained leadership positions in their respective markets.

Piramal Pharma Limited

Piramal Pharma Limited announced its standalone and consolidated results for Q1 FY27, with a 17% revenue growth, 72% EBITDA increase, and 12.5% EBITDA margin expansion.

Piramal Pharma Limited

Piramal Pharma Limited has announced its unaudited financial results for the quarter ended June 30, 2026, with revenue from operations at Rs. 1,124.95 crores and net profit after tax at Rs. 113.48 crores.

Piramal Pharma Limited

Piramal Pharma Limited has granted 56,36,436 stock options to employees under the Employee Stock Option and Incentive Plan 2022. The options have been granted at an exercise price of Rs.10/- per option and will be exercisable within 5 years commencing from the date of vesting of each tranche.

Piramal Pharma Limited

Piramal Pharma Limited has temporarily suspended operations at its manufacturing facilities in Ahmedabad, Gujarat, due to heavy rainfall and flooding. The company has initiated actions to assess the situation and resume operations safely. The affected facilities account for less than 3% of the company's consolidated revenues.

Piramal Pharma Limited

Piramal Pharma Limited has informed the Exchange about the schedule of a conference call with investors/analysts to discuss its Q1 FY2027 Results on 30th July 2026.

Piramal Pharma Limited

Piramal Pharma Limited has successfully closed a US FDA inspection at its manufacturing facility in Sellersville, USA, with the issuance of an Establishment Inspection Report (EIR).

Piramal Pharma Limited

Piramal Pharma Limited has published a newspaper advertisement for the dispatch of notice of the 6th Annual General Meeting (AGM) and e-voting information, as per Regulation 30 of the SEBI Listing Regulations. The AGM is scheduled to be held on July 30, 2026, through video conference or other audio-visual means. The company also requests shareholders to update their Know Your Customer (KYC) details and claim unpaid dividends to prevent transfer to the Investor Education and Protection Fund (IEPF).

Piramal Pharma Limited

Piramal Pharma Limited has submitted its Business Responsibility & Sustainability Report for the financial year 2025-26, as per the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Piramal Pharma Limited

Piramal Pharma Limited has announced its 6th Annual General Meeting (AGM) and Annual Report for the financial year 2025-26, which will be held on July 30, 2026, through video conferencing.

Piramal Pharma Limited

Piramal Pharma Limited's promoter, Ajay G. Piramal, has submitted a declaration under SEBI Takeover Regulations stating that the promoter group has not made any encumbrance on the company's shares during the financial year 2025-2026.